Lataa...
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
INTRODUCTION: Abiraterone and enzalutamide were approved by the Food and Drug Administration in 2011 and 2012 to treat men with metastatic castration-resistant prostate cancer (mCRPC). Most men with mCRPC are > 65 years of age and thus eligible for Medicare Part D. We conducted a study to better...
Tallennettuna:
| Julkaisussa: | J Oncol Pract |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Clinical Oncology
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5555032/ https://ncbi.nlm.nih.gov/pubmed/28628393 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.2016.020206 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|